{"nctId":"NCT00337818","briefTitle":"Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women","startDateStruct":{"date":"2006-06"},"conditions":["Papillomavirus Type 16/18 Infection","Cervical Intraepithelial Neoplasia"],"count":770,"armGroups":[{"label":"Cervarix New Process","type":"EXPERIMENTAL","interventionNames":["Biological: Cervarix™"]},{"label":"Cervarix Old Process Group","type":"EXPERIMENTAL","interventionNames":["Biological: Cervarix™"]},{"label":"Cervarix Young/Lot 1 Group","type":"EXPERIMENTAL","interventionNames":["Biological: Cervarix™"]}],"interventions":[{"name":"Cervarix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A female who enrolled in the HPV-012 (NCT00337818) study in Denmark, Estonia and Finland, received three doses of vaccine and completed Visit 4 (Month 7).\n* Written informed consent obtained from the subject prior to enrolment (for subjects below the legal age of consent, written informed consent must be obtained from a parent or legally acceptable representative (LAR) and, in addition, the subject must sign and personally date a written informed assent).\n\nExclusion criteria\n\n* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Chronic administration of immunosuppressants or other immune-modifying drugs occurring less than three months prior to blood sampling.\n* Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"10 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).\n\n\\*Data for Month 18 outcome variables were incorporated into the Month 24 analyses.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1440.4","spread":null},{"groupId":"OG001","value":"1903.7","spread":null},{"groupId":"OG002","value":"3861.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1397.5","spread":null},{"groupId":"OG001","value":"1679.3","spread":null},{"groupId":"OG002","value":"3353.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1140.9","spread":null},{"groupId":"OG001","value":"1427.3","spread":null},{"groupId":"OG002","value":"2862.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"649.8","spread":null},{"groupId":"OG001","value":"778.8","spread":null},{"groupId":"OG002","value":"1341.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"574.7","spread":null},{"groupId":"OG001","value":"649.6","spread":null},{"groupId":"OG002","value":"1111.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"462.4","spread":null},{"groupId":"OG001","value":"519.9","spread":null},{"groupId":"OG002","value":"935.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervical Samples","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"107.5","spread":null},{"groupId":"OG002","value":"198.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null},{"groupId":"OG001","value":"62.1","spread":null},{"groupId":"OG002","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"94.5","spread":null},{"groupId":"OG002","value":"129.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"31.9","spread":null},{"groupId":"OG002","value":"107.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"29.6","spread":null},{"groupId":"OG002","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies in Blood Samples","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1403.1","spread":null},{"groupId":"OG001","value":"1490.5","spread":null},{"groupId":"OG002","value":"5399.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1291.8","spread":null},{"groupId":"OG001","value":"1435.0","spread":null},{"groupId":"OG002","value":"3733.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1047.3","spread":null},{"groupId":"OG001","value":"1950.5","spread":null},{"groupId":"OG002","value":"3332.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"584.5","spread":null},{"groupId":"OG001","value":"648.6","spread":null},{"groupId":"OG002","value":"1814.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"555.4","spread":null},{"groupId":"OG001","value":"542.1","spread":null},{"groupId":"OG002","value":"1163.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"478.4","spread":null},{"groupId":"OG001","value":"805.4","spread":null},{"groupId":"OG002","value":"1048.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Pregnancies, New Onset Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)","description":"NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes. MSCs assessed include adverse events prompting emergency room or physician visits that are not related to common diseases or serious adverse events (SAEs) that are not related to common diseases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting SAEs","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":186},"commonTop":[]}}}